Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (1953)	7/23/1999 9:46:00 PM
From: Don Dorsey	Read Replies (1) \| Respond to of 2135

Since the topic of biologists has come up, I've had an interesting experience in talking to several. They are so tied into the idea of incrementally extending survival rates, that they dismiss the possibility of a cure without consideration. History suggests that when cancer is finally cured it will be sudden, and by some breakthrough treatment, not by the slow process of extending life expectancy a few weeks at a time. I have no idea if what ENMD is doing will work, but when a cure comes, I expect that it will burst on the scene in much the same way, and amid as much disbelief as ENMD. If nothing else, what we are witnessing in ENMD right now is preparation to what we will witness when a cure is finally found.

To: tommysdad who wrote (1953)	7/24/1999 7:00:00 PM
From: EPro	Read Replies (1) \| Respond to of 2135

I think you have pin-pointed what is going to be the basis flaw with this stock -- everyone's expectations are too high. If the trials show anything less than overnight cure, this stock will plunge, because everyone is thinking over-night cure. Even "very good" or "promising" results will cause it to tank, because of the excess in expectations. I say this even tho I'm long the stock, and reasonably well informed on the science. Its too bad, but this is what happens when a stock gets taken over by zealots (i.e., see the Yahoo thread) Even if phase I shows "good" results, with promise a couple or few years down the line, the disappointment over the lack of a home run will be deadly for the price.